Clinical Trial Update: A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the pharmacokinetics and safety of LY3537031 in healthy participants and those with renal impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Renal Insufficiency

Drugs mentioned

• LY3537031 (LY3537031)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Renal Impairment, Healthy | Phase 1 | Status: COMPLETED